2016
Offline
Online
Molecular markers that have been identified in prognosis and risk of relapse in localized prostate cancer.
Date added (newest)
Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy proved efficacious, progression-free survival by PD-L1 group
Microbiome Effects of Antibodies Can Linger for Up to 60 Days Push a start date to allow time between antibiotic use and immunotherapy
Using Microbiome Transplantation or FMT for RCC They should still benefit from their given immunotherapy with additional supplements
Systemic Therapy in Metastatic Renal Cell Carcinoma Antibiotic use does affect outcomes in patients
Subgroup analyses of METEOR
CheckMate 025 phase III trial
Immunotherapy in non muscle invasive bladder cancer #GU16
How soon should we expect approval of immunotherapy in urothelial cancer #GU16
Future role of immunotherapy and checkpoint inhibitors in urothelial cancer #GU16
Atezolizumab shows very significant activity in advanced urothelial cancer #GU16
Discontinuing VEGF-TT for progression versus toxicity impacts outcomes of second-line therapies in mRCC #GU16
Genomics in urothelial carcinomas may play much bigger role in the future #GU16
My videos
Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy proved efficacious, progression-fre...
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy proved efficacious, progression-free survival by PD-L1 group at the 2018 ASCO.
